Evelo Biosciences Stock (NASDAQ:EVLO)
Previous Close
-
52W Range
- - $0.70
50D Avg
-
200D Avg
$0.02
Market Cap
$28.47K
Avg Vol (3M)
$1.16K
Beta
1.30
Div Yield
-
EVLO Company Profile
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
EVLO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ASMB | Assembly Biosciences, Inc. |
| NLTX | Neurogene Inc. |
| ENSC | Ensysce Biosciences, Inc. |
| ALRN | Aileron Therapeutics, Inc. |
| CTMX | CytomX Therapeutics, Inc. |
| BXRX | Baudax Bio, Inc. |
| APTX | Aptinyx Inc. |
| WINT | Windtree Therapeutics, Inc. |
| MGTA | Dianthus Therapeutics, Inc. |
| PCSA | Processa Pharmaceuticals, Inc. |
| KRON | Kronos Bio, Inc. |